| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e96496a9949403e2af2ca913e65bfec |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6931 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 |
| filingDate |
2018-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e5d028ca1999565f2ff51a3a8992b46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6b7759cd0efa2122826c6c33481f28e |
| publicationDate |
2021-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10934547-B2 |
| titleOfInvention |
Use of trinucleotide repeat RNAs to treat cancer |
| abstract |
Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and/or growth. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11312958-B2 |
| priorityDate |
2017-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |